| ABSTRACT Objective:To systemically assess the effect of an aerosol inhalation of Shuanghuanglian injection in treatment of upper respiratory infections. Methods:The quality of included literatures was evaluate, and valid data were extracted. Databases, including CNKI, VIP, WanFang Data were searched to collect randomized controlled trials (RCTs) from January 1, 2000 to November 15, 2015. Studies were screened, data were extracted, and the methodological quality was assessed by two reviewers independently. Meta analyses were conducted by using Stata 12.0 soft ware.Results:16 RCTs including 1 661 patients were included finally. All of the trials described baseline were comparable. With Cochrane scales, 16 trials scored B degree. Compared with the control group, aerosol inhalation of Shuanghuanglian injection preferably improved the clinical total effective rate (OR＝1.30, 95%CI：1.13-1.50, P<0.001). Adverse drug reactions were not mentioned in 15 studies, were not observed in 1 study. Conclusion:Aerosol inhalation of Shuanghuanglian injection for treating upper respiratory infections is superior to blank group, gentamycin or gentamycin combined with dexamethasone. However, its long term curative effect and more comprehensive safety still needs to be further verified by more large sample and high quality RCTs. |
